All In Biotech

Drug Trial Radar · NCT06551246

Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)

Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Overactive Bladder and Daytime Urinary Incontinence (BeDry)

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

236

Planned (sponsor's estimate)

Start

Jun 27, 2024

Primary completion

Oct 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose. In total, 236 children diagnosed with daytime urinary incontinence will be randomized 1:1:1:1 to one of four treatment groups. Total pharmacological treatment period will be 18 weeks.

Conditions

  • Urinary Incontinence in Children

Interventions

  • SolifenacinDrug

    According to randomization.

  • MirabegronDrug

    According to randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment responseTime frame: From study week 6 and through study completion, an average of 18 weeks in total

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Pediatric and Adolescent Medicine, Aalborg University Hospital

    Aalborg, Aalborg, Denmark · Recruiting

  • Department of Pediatric and Adolescent Medicine, Aarhus University Hospital

    Aarhus, Aarhus N, Denmark · Recruiting

  • Department of Pediatric and Adolescent medicine, Esbjerg Hospital

    Esbjerg, Esbjerg, Denmark · Recruiting

  • Department of Pediatric and Adolescent Medicine, Gødstrup Hospital

    Herning, Herning, Denmark · Recruiting

  • Department of Pediatric and Adolescent Medicine, Kolding Hospital

    Kolding, Kolding, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.